These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 14506192

  • 1. Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT.
    DeNardo SJ, DeNardo GL, Yuan A, Richman CM, O'Donnell RT, Lara PN, Kukis DL, Natarajan A, Lamborn KR, Jacobs F, Siantar CL.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3938S-44S. PubMed ID: 14506192
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of a cathepsin-cleavable peptide linked radioimmunoconjugate of a panadenocarcinoma MAb, m170, in mice and patients.
    DeNardo GL, DeNardo SJ.
    Cancer Biother Radiopharm; 2004 Feb 01; 19(1):85-92. PubMed ID: 15068616
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.
    Richman CM, Denardo SJ, O'Donnell RT, Yuan A, Shen S, Goldstein DS, Tuscano JM, Wun T, Chew HK, Lara PN, Kukis DL, Natarajan A, Meares CF, Lamborn KR, DeNardo GL.
    Clin Cancer Res; 2005 Aug 15; 11(16):5920-7. PubMed ID: 16115934
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer.
    DeNardo SJ, Richman CM, Albrecht H, Burke PA, Natarajan A, Yuan A, Gregg JP, O'Donnell RT, DeNardo GL.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 2):7187s-7194s. PubMed ID: 16203820
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Preclinical evaluation of cathepsin-degradable peptide linkers for radioimmunoconjugates.
    DeNardo GL, DeNardo SJ, Peterson JJ, Miers LA, Lam KS, Hartmann-Siantar C, Lamborn KR.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3865S-72S. PubMed ID: 14506184
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.
    Denardo SJ, Richman CM, Goldstein DS, Shen S, Salako Q, Kukis DL, Meares CF, Yuan A, Welborn JL, Denardo GL.
    Anticancer Res; 1997 Sep 01; 17(3B):1735-44. PubMed ID: 9179227
    [Abstract] [Full Text] [Related]

  • 11. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
    DeNardo GL, O'Donnell RT, Shen S, Kroger LA, Yuan A, Meares CF, Kukis DL, DeNardo SJ.
    J Nucl Med; 2000 May 01; 41(5):952-8. PubMed ID: 10809213
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL, Govindan SV, Sharkey RM, Fisher DR, Goldenberg DM.
    J Nucl Med; 2003 Jan 01; 44(1):77-84. PubMed ID: 12515879
    [Abstract] [Full Text] [Related]

  • 14. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates.
    Kukis DL, DeNardo SJ, DeNardo GL, O'Donnell RT, Meares CF.
    J Nucl Med; 1998 Dec 01; 39(12):2105-10. PubMed ID: 9867151
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry.
    Shen S, DeNardo SJ, Richman CM, Yuan A, Siantar CH, O'Donnell RT, Kroger LA, DeNardo GL.
    J Nucl Med; 2005 Jun 01; 46(6):1034-41. PubMed ID: 15937317
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Antibody responses to macrocycles in lymphoma.
    DeNardo GL, Mirick GR, Kroger LA, O'Donnell RT, Meares CF, DeNardo SJ.
    J Nucl Med; 1996 Mar 01; 37(3):451-6. PubMed ID: 8772643
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.